Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00375050 · ClinicalTrials.gov registry record · NA
Treatment of Refractory Schizophrenia With Riluzole
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT00375050 is a NA study that has completed, run by Yale University. The registered enrollment target is 34 participants.
The verdict
NCT00375050, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
The proposed study would evaluate the benefits of riluzole add-on treatment to patients with schizophrenia who are already receiving medications, but still experience symptoms. Neuroprotective medication riluzole is currently approved for treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease), a severe neurological illness. Due to its unique mechanism of action, riluzole, if effective in helping the symptoms of schizophrenia, would open novel directions in treatment of schizophrenia.
Interventions
- DRUG Placebo
- DRUG Riluzole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2002-05 |
| Est. Completion | 2006-08-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00375050
The ClinicalTrials.gov registry entry for NCT00375050 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00375050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00375050 about?
NCT00375050 is a clinical study titled "Treatment of Refractory Schizophrenia With Riluzole". The proposed study would evaluate the benefits of riluzole add-on treatment to patients with schizophrenia who are already receiving medications, but still experience symptoms. Neuroprotective medication riluzole is currently approved for treatment of amyotrophic lateral sclerosis (Lou Gehrig's dise...
What is the current status of trial NCT00375050?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2002-05. Estimated completion is 2006-08-29.
What interventions are being tested in trial NCT00375050?
The interventions under investigation include: Placebo (DRUG), Riluzole (DRUG).
Who is sponsoring clinical trial NCT00375050?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.